NDAORALTABLET
Approved
Jul 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LO/OVRAL FE (ethinyl estradiol; levonorgestrel; ferrous fumarate) by Cadence Neuroscience is ovulation. First approved in 1979.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO/OVRAL FE is an oral contraceptive combination tablet containing ethinyl estradiol and levonorgestrel, with added ferrous fumarate for iron supplementation. It prevents ovulation to provide contraceptive efficacy. This product is indicated for pregnancy prevention in women of reproductive age.
LOE Approaching
This mature contraceptive facing LOE will likely have a smaller, focused brand team managing decline and potential transition to generic support.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LO/OVRAL FE offers limited growth opportunity given its LOE status and zero linked job openings. Career impact is defensive—roles focus on managed decline, generic transition, and customer retention rather than expansion or innovation.
Brand ManagerPharmacy Manager
Worked on LO/OVRAL FE at Cadence Neuroscience? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.